Trial Profile
A prospective, case-control pilot study of fingolimod (gilenya) on cognitive function in patients with relapsing multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 23 Feb 2016 New trial record